Key vendors to increase their sales by introducing regenerative medicine-based biologics
Technavio, a company that develops over 2000 pieces of research every year and covers more than 500 technologies across 80 countries, has announced the top five leading vendors for the global musculoskeletal disorder therapeutics market in their latest research report. This report also lists 98 other prominent vendors who are expected to contribute to this market’s growth between 2016-2020.
To identify the top vendors, Technavio’s market research analysts have taken into account the revenue generated by the sales of branded, generic, and off-label drugs used to treat musculoskeletal disorders.
- Biologics: They have a complex structure that does not allow easily identification or characterization, and are mostly thermo-labile and susceptible to microbial contamination.
- Small molecules: These are chemical entities that have low molecular weight and a less complex structure. These are manufactured easily through chemical synthesis, mostly nonimmunogenic and fairly stable in nature.
This Technavio report, under cardiovascular and metabolic disorders vertical, is based on the synthesis, analysis, and interpretation of information about the global musculoskeletal disorder therapeutics market collected from specialized sources. The analysts have derived insights using a mix of primary and secondary research with an aim to provide a holistic picture of the market.
Click here to request a free sample of this report
Competitive vendor landscape
The global vendors lead the market with innovative product launches that counter the side-effects of biologic drugs. Companies are forming merger and acquisitions to introduce cost-effective drugs that have a wider customer reach. Furthermore, joint efforts by the vendors and the US FDA to launch new innovative products will further contribute to the development of the global musculoskeletal disorder therapeutics market during the forecast period. For instance, DiscGenics developed drugs for musculoskeletal disorders using Discosphere Technology, which helps in isolating stem-like progenitor cells from human adult intervertebral disc tissue, and regenerates new intervertebral disc material.
“Various companies and research organizations are implementing innovative technologies to develop regenerative medicines. In recent times, the introduction of synthetic biology technology platform is being utilized to develop and commercialize genetically modified chondrocyte cell therapeutics,’ says Barath Palada, a lead analyst at Technavio for research on cardiovascular and metabolic disorders.
Top five vendors in the musculoskeletal disorder therapeutics market space
AbbVie
This company develops and promotes advanced therapies that treat complex and serious diseases. The therapeutic drugs are used to treat chronic autoimmune diseases, oncology, virology, neurological disorders, metabolic diseases, and other serious health conditions. Recently, AbbVie and Boehringer Ingelheim announced a collaboration agreement to develop and commercialize BI 655066 to treat Crohn’s disease, psoriatic arthritis, and asthma.
Key products: Humira.
Johnson & Johnson
The company develops products across the infectious diseases, immunology, oncology, neuroscience, metabolic, and cardiovascular diseases therapy areas. It sells products like Remicade, Simponi, Simponi Aria, and Stelara. The company’s strategic initiatives such as new product launches, expansions, and alliances are expected to fuel its market share.
Key products: Remicade, Simponi, Simponi Aria, and Stelara.
Amgen
Amgen focuses on therapeutic areas such as cancer, bone disease, kidney disease, and rheumatoid arthritis. In the recent times, Amgen and UCB announced positive Phase III results of the investigational agent romosozumab in comparison with teriparatide in treating postmenopausal osteoporosis.
Key products: Enbrel and Prolia.
Pfizer
The company manufactures pharmaceutical products for arthritis, cardiovascular, metabolic, infectious, and respiratory therapy areas. The products that is offered in the market are Lyrica, Enbrel, Celebrex, and Xeljanz. They also offer other products to treat musculoskeletal disorders such as Arthrotec, Daypro, Feldene, and Motrin.
Key products: ANSAID, Arthrotec, Celebrex, Daypro, Enbrel, Feldene, Lyrica, Motrin, and Xeljanz
F. Hoffmann-La Roche
F. Hoffmann-La Roche operates its two main line of business; pharmaceuticals and diagnostics.. The company recently entered into a partnership with NHS researchers to discover whether a drug traditionally prescribed for individuals with arthritis can also benefit those with an incurable heart disease or pulmonary hypertension.
Key products: MabThera/Rituxan and Actemra/RoActemra.
Other prominent vendors in the market are 3SBio, AB Sciences, AbGenomics International, Ablynx, Adheron, Akron Molecules, Alder BioPharmaceuticals, Amgen Astellas BioPharma, Ampio Pharmaceuticals, Antares Medical Services, Astellas, AstraZeneca, Baxter, Biocad, Bioiberica, Boehringer Ingelheim, Bone Therapeutics, Can-Fite BioPharma, Celgene Corporation, Celltrion, Cellular Biomedicine, Cerapedics, ChemoCentryx, Chugai Pharmaceutical, Coherus Biosciences, Daiichi Sankyo, Dong-A ST, Edding Pharm, Eisai, Epirus, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gedeon Richter, Gilead Sciences, GlaxoSmithKline, Histogenics, IBSA Institut Biochimique, iCeutica, Iltoo Pharma, Incyte Corporation, Innovative Med Concepts, Iroko Pharmaceuticals, ISTO Technologies, KaloBios Pharmaceuticals, KAN Research Institute, Kang Stem Biotech, Kitov Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, MEDIPOST, Medivir, Merck, Mereo, Mesoblast, MOCHIDA PHARMACEUTICAL, MorphoSys, Morphotek, Mycenax, Neomed Institute, Novartis, Omeros Corporation, OrthoTrophix, Osteologix, OxyPharma, PFEnex, Philogen, PhytoHealth Corporation, Plexxikon, PLx Pharma, Protalex, Proximagen Limited, Radius Health, Regeneron Pharmaceuticals, Samsung Bioepis, Samumed, Sandoz, Sanofi, SantoSolve AS, Steminent Biotherapeutics, Stempeutics Research, Taisho Pharmaceutical, Taiwan Liposome Company, Takeda, Tarsa Therapeutics, Techfields Pharma, Tetec , TheraMAB, TiGenix, TissueGene, Tonix Pharmaceuticals, Translational Biosciences, UCB, Vericel, Vertex Pharmaceuticals, Vitaeris, Winston Laboratories, and Zosano Pharma Corporation
To read more press releases- click here.
Browse related reports:
- Global Anxiety Disorders Market 2015-2019
- Global Biologic Therapeutics Market 2015-2019
- Global Bipolar Disorder Therapeutics Market 2015-2019
For any assistance or query, please contact our media team at:
US: +1 630 333 9501
UK: +44 208 123 1770
